Dr. Scott C. Feitell, D.O.
Heart Failure & Transplant Cardiology (Advanced Heart Failure and Transplant Cardiology Physician)
- Medicare participating
At a glance
- Medical school
- Philadelphia College of Osteopathic Medicine (2009)
- Years since graduation
- 17
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 206
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Medical school: Philadelphia College of Osteopathic Medicine
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Advanced Heart Failure and Transplant Cardiology Physician primary
NC license 2026-04122 · NY license 282955 -
Cardiovascular Disease Physician
NY license 282955 -
Hospitalist Physician
NY license 282955 -
Internal Medicine Physician
PA license OTO13187
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Heart Failure & Transplant Cardiology per capita by county →
Where they work
Hospitals
- Strong Memorial Hospital Rochester, NY
- Rochester General Hospital Rochester, NY
- Unity Hospital Rochester, NY
- Cayuga Medical Center at Ithaca Ithaca, NY
- Newark-Wayne Community Hospital Newark, NY
Medical groups
- Rochester General Hospital (1,182 clinicians)
- Western New York Medical Practice PC (524 clinicians)
- The Presbyterian Hospital (414 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 206
- Services billed
- 1,239
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Anticoagulant management of patient taking warfarin | 852 | 29 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 87 | 42 |
| Established patient office or other outpatient visit, 30-39 minutes | 84 | 65 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 57 | 39 |
| Critical care, first 30-74 minutes | 39 | 19 |
| Established patient office or other outpatient visit, 40-54 minutes | 26 | 25 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 23 | 22 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 23 | 23 |
| Insertion of tube in right heart chambers for measurement | 20 | 19 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 16 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Spironolactone Other prescribers in Charlotte, NC | 135 |
| Entresto (sacubitril/valsartan) Other prescribers in Charlotte, NC | 90 |
| Metoprolol Succinate Other prescribers in Charlotte, NC | 85 |
| Torsemide Other prescribers in Charlotte, NC | 64 |
| Jardiance (empagliflozin) Other prescribers in Charlotte, NC | 61 |
| Carvedilol Other prescribers in Charlotte, NC | 42 |
| Digoxin Other prescribers in Charlotte, NC | 40 |
| Atorvastatin Calcium Other prescribers in Charlotte, NC | 38 |
| Rosuvastatin Calcium Other prescribers in Charlotte, NC | 35 |
| Ezetimibe Other prescribers in Charlotte, NC | 35 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 127 payments worth $52,966 in total to this clinician.
| Bridgebio Pharma, Inc. | $15,065 |
|---|---|
| Actelion Pharmaceuticals US, Inc. | $12,587 |
| Alnylam Pharmaceuticals Inc. | $8,208 |
| Pfizer Inc. | $8,128 |
| Scpharmaceuticals Inc. | $4,847 |
| Impulse Dynamics (USA) Inc. | $2,821 |
| Cvrx, Inc. | $310 |
| Merck Sharp & Dohme LLC | $182 |
| Compensation for services other than consulting (speaking, faculty) | $42,265 |
|---|---|
| Honoraria | $6,150 |
| Food and Beverage | $3,241 |
| Consulting Fee | $1,000 |
| Travel and Lodging | $310 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Mar 18, 2025 | Compensation for services other than consulting (speaking, faculty) VYNDAQEL · CARDIOVASCULAR | $4,250 |
| Scpharmaceuticals Inc. Apr 1, 2025 | Honoraria FUROSCIX · Cardiology | $4,200 |
| Alnylam Pharmaceuticals Inc. Jul 17, 2025 | Compensation for services other than consulting (speaking, faculty) AMVUTTRA · Genetic Disease | $3,150 |
| Alnylam Pharmaceuticals Inc. Oct 1, 2025 | Compensation for services other than consulting (speaking, faculty) AMVUTTRA · Genetic Disease | $3,150 |
| Pfizer Inc. Apr 28, 2025 | Compensation for services other than consulting (speaking, faculty) VYNDAQEL · CARDIOVASCULAR | $3,125 |
| Actelion Pharmaceuticals US, Inc. Apr 24, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $2,940 |
| Bridgebio Pharma, Inc. Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $2,595 |
| Bridgebio Pharma, Inc. Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $2,595 |
| Bridgebio Pharma, Inc. May 22, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $2,595 |
| Bridgebio Pharma, Inc. Oct 8, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $2,595 |
All 27 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Bridgebio Pharma, Inc. Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $1,730 |
| Bridgebio Pharma, Inc. Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $2,595 |
| Bridgebio Pharma, Inc. Nov 7, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $2,595 |
| Scpharmaceuticals Inc. Nov 3, 2025 | Honoraria FUROSCIX · Cardiology | $350 |
| Actelion Pharmaceuticals US, Inc. Oct 29, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $2,520 |
| Impulse Dynamics (USA) Inc. Oct 17, 2025 | Consulting Fee Optimizer; Optimizer · Cardiovascular Device | $1,000 |
| Actelion Pharmaceuticals US, Inc. Oct 9, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $2,520 |
| Bridgebio Pharma, Inc. Oct 8, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $2,595 |
| Bridgebio Pharma, Inc. Oct 8, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $1,298 |
| Alnylam Pharmaceuticals Inc. Oct 1, 2025 | Compensation for services other than consulting (speaking, faculty) AMVUTTRA · Genetic Disease | $3,150 |
| Alnylam Pharmaceuticals Inc. Oct 1, 2025 | Travel and Lodging AMVUTTRA · Genetic Disease · travel to Amherst, NY | $105 |
| Alnylam Pharmaceuticals Inc. Jul 17, 2025 | Compensation for services other than consulting (speaking, faculty) AMVUTTRA · Genetic Disease | $3,150 |
| Actelion Pharmaceuticals US, Inc. Jun 6, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $840 |
| Alnylam Pharmaceuticals Inc. Jun 2, 2025 | Compensation for services other than consulting (speaking, faculty) AMVUTTRA · Genetic Disease | $630 |
| Bridgebio Pharma, Inc. May 22, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $2,595 |
| Bridgebio Pharma, Inc. May 22, 2025 | Compensation for services other than consulting (speaking, faculty) Attruby · Cardiomyopathy | $1,298 |
| Pfizer Inc. Apr 28, 2025 | Compensation for services other than consulting (speaking, faculty) VYNDAQEL · CARDIOVASCULAR | $3,125 |
| Actelion Pharmaceuticals US, Inc. Apr 25, 2025 | Travel and Lodging UPTRAVI; OPSUMIT · Cardiology · travel to Amherst, NY | $96.74 |
| Actelion Pharmaceuticals US, Inc. Apr 24, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $2,940 |
| Actelion Pharmaceuticals US, Inc. Apr 22, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $420 |
| Impulse Dynamics (USA) Inc. Apr 15, 2025 | Honoraria Optimizer; Optimizer · Cardiovascular Device | $1,600 |
| Actelion Pharmaceuticals US, Inc. Apr 3, 2025 | Compensation for services other than consulting (speaking, faculty) UPTRAVI; OPSUMIT · Cardiology | $2,520 |
| Alnylam Pharmaceuticals Inc. Apr 2, 2025 | Compensation for services other than consulting (speaking, faculty) | $945 |
| Scpharmaceuticals Inc. Apr 1, 2025 | Honoraria FUROSCIX · Cardiology | $4,200 |
| Scpharmaceuticals Inc. Apr 1, 2025 | Travel and Lodging FUROSCIX · Cardiology · travel to AMHERST, NY | $109 |
| Pfizer Inc. Mar 18, 2025 | Compensation for services other than consulting (speaking, faculty) VYNDAQEL · CARDIOVASCULAR | $4,250 |
| Pfizer Inc. Jan 17, 2025 | Compensation for services other than consulting (speaking, faculty) VYNDAMAX · CARDIOVASCULAR | $550 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.